



COMPANY OVERVIEW

Cerecor is a biopharmaceutical company developing innovative therapies at the cutting edge of science. Our pipeline, filled with forward-thinking ideas, propels us forward. We are driven to change the lives of patients with rare pediatric and orphan diseases.

RECENT NEWS

Cerecor to Present at Upcoming Investor Conferences

Sep 10 2020, 7:00 AM EDT

Cerecor Resumes Phase 1b Clinical Trial of CERC-002 for the Treatment of Severe Pediatric Onset Crohn's Disease

Aug 26 2020, 7:00 AM EDT

STOCK OVERVIEW

Symbol	CERC
Exchange	Nasdaq
Market Cap	185.06m
Last Price	\$2.43
52-Week Range	\$1.52 - \$6.19

09/25/2020 04:00 PM EDT

INVESTOR RELATIONS

ir@cerecor.com

MANAGEMENT TEAM

Michael Cola

Chief Executive Officer

James A. Harrell, Jr.

Chief Commercial Officer

Dr. Garry Neil, MD

Chief Scientific Officer

Chris Sullivan

Interim Chief Financial Officer

H. Jeffrey Wilkins, MD

Chief Medical Officer

CERECOR, INC.

540 Gaither Road
Suite 400
Rockville, MD 20850

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.